FDA conducted 1,248 drug quality assurance inspections in FY2025, up from 972 in FY2024. Therefore, pharmaceutical capital projects need stronger control over design, qualification, validation, and operational readiness. As a result, pharma project consultants help teams manage complex upgrades and technology transfers without losing GMP control. Meanwhile, specialized pharma consultancy services can align engineering, QA, validation, schedules, and compliance before inspection pressure exposes costly gaps.
Table of Contents
What Do Pharma Project Consultants Do?
Pharma project consultants help pharmaceutical companies plan, control, and deliver complex regulated projects. They combine pharmaceutical project management with engineering, quality, validation, and GMP expertise. Therefore, they can identify technical and compliance risks before these issues affect timelines or regulatory readiness. They also coordinate teams during facility upgrades, technology transfers, equipment installation, qualification, and process validation. In addition, consultants align project decisions with GMP requirements and business goals. As a result, companies gain stronger project control from early planning through commissioning, validation, operational readiness, and final handover.
How Project Gaps Become GMP Risks
Small project gaps can quickly become serious GMP risks in pharmaceutical operations. Poor planning may delay critical activities, while unclear ownership can leave quality actions unresolved. In addition, uncontrolled changes may affect validated systems, equipment, or processes without proper impact assessment. Delayed validation can also postpone release or operational readiness. Meanwhile, incomplete documentation weakens traceability and inspection evidence. Therefore, strong project governance should connect planning, change control, validation, documentation, and accountability throughout the project lifecycle.
This infographic shows how common project gaps can escalate into GMP compliance risks when planning, validation, change control, and documentation are not properly managed.
Four Controls That Determine GMP Project Readiness
Strong GMP project readiness depends on four controls that keep technical work, quality decisions, and compliance evidence aligned throughout execution.
The table below summarizes the four key controls that support GMP project readiness and reduce compliance risks throughout project execution.
- GMP Project Governance and Risk Control (PDF)
- Pharmaceutical Technology Transfer Planning (PDF)
- Qualification of Facilities and Equipment (PDF)
- Process Validation Before Routine Manufacturing (PDF)
GMP Project Governance and Risk Control (PDF)
Defines responsibilities, decision-making, and risk-based controls to keep projects compliant and quality-focused.
Download ICH Harmonised Guideline: Quality Risk Management Q9(R1) Here
Pharmaceutical Technology Transfer Planning (PDF)
Structures the transfer of product, process, analytical, and manufacturing knowledge between sites or teams.
Download WHO Guidelines on Technology Transfer in Pharmaceutical Manufacturing Here
Qualification of Facilities and Equipment (PDF)
Confirms that facilities, utilities, equipment, and systems are designed, installed, operated, and performing as intended.
Process Validation Before Routine Manufacturing (PDF)
Demonstrates that the manufacturing process can consistently produce products that meet predefined quality requirements.
Download Guidance for Industry: Process Validation: General Principles and Practices Here
How to Choose a Pharma Project Consultant
Choosing the right pharma project consultant requires more than reviewing a CV or project list. Companies should assess proven pharmaceutical experience, project-management capability, engineering knowledge, validation expertise, and practical GMP understanding. In addition, the consultant should communicate clearly across QA, engineering, operations, and leadership teams. Strong candidates should also provide evidence from comparable regulated projects. Therefore, selecting a consultant with both technical depth and GMP project experience can reduce execution risks, improve compliance, and support smoother project delivery.
What Should a Pharma Project Engagement Deliver?
A successful pharma project engagement should leave the site ready to operate, not simply mark project activities as complete. The team should deliver qualified systems, validated processes, approved controls, and documented risk decisions. In addition, technical knowledge and responsibilities should transfer clearly to site teams. Therefore, final handover should provide traceable GMP evidence that QA, engineering, validation, and operations can maintain after the consultant leaves.
The table below shows the key deliverables that should demonstrate controlled, compliant, and sustainable project handover.
| Project Deliverable | What Should Be in Place at Handover | Why It Matters for GMP |
|---|---|---|
|
Approved Project Controls |
Approved plans, controlled changes, documented deviations, risk tracking, and clear approvals. |
Keeps project execution controlled and prevents unmanaged GMP risks. |
|
Qualified Facilities and Systems |
Required qualification activities, such as DQ, IQ, OQ, and PQ, are completed and approved. |
Confirms that facilities, utilities, equipment, and systems are fit for intended use. |
|
Validated Processes |
Validation studies meet predefined acceptance criteria and demonstrate consistent process performance. |
Provides evidence that the process can reliably deliver the required product quality. |
|
Controlled and Closed Risks |
Critical risks are assessed, mitigation actions are completed, and residual risks are formally accepted. |
Prevents unresolved quality or compliance risks from entering routine operations. |
|
Traceable GMP Evidence and Ownership |
Final records, approvals, responsibilities, training, and handover documentation are complete and accessible. |
Supports inspection readiness and ensures continued control after project completion. |
This structure is grounded in EU GMP Annex 15 requirements for lifecycle qualification, validation planning, documented responsibilities, deviations, and formal progression between stages; FDA’s lifecycle approach to process validation; ICH Q9/Q10 principles for risk, responsibility, knowledge, and change management; and WHO technology-transfer expectations for documented roles and transfer of technical knowledge.
This infographic shows how structured project planning, qualification, validation, and handover move a pharmaceutical project toward full GMP readiness.
Final Words
In FY2025, FDA classified 18% of drug quality inspections as Official Action Indicated (OAI). This finding shows why project decisions must withstand regulatory scrutiny long after installation and handover. Therefore, pharma project consultants can add value by connecting governance, qualification, validation, and documentation before gaps reach routine operations. Ultimately, strong project control makes GMP readiness a planned outcome rather than a late-stage correction.
Qualification and Validation for GMP Systems
Our team supports the planning, execution, and maintenance of qualification and validation activities, including IQ, OQ, and PQ, to keep GMP-regulated systems compliant and under control.
FAQ
Hire one for complex GMP upgrades, technology transfer, qualification, validation, or inspection-readiness projects, ideally before execution starts.
Complete qualification, required validation, risk closure, change documentation, ownership transfer, and traceable GMP records before handover.
Look for proven experience in CQV, process validation, technology transfer, GMP compliance, and successful regulated project delivery.
References
Marco Klinger is Head of Quality Services at Zamann Pharma Support, where he leads consulting teams through complex regulatory and quality-driven projects. He brings more than 15 years of hands-on compliance experience across regulated industries. His work includes close collaboration with companies such as Reckitt, Sanofi, Biotech, Biotest, and others. Marco has deep expertise in medical device development, aseptic manufacturing, and the design, implementation, and management of complete quality management systems within GMP-regulated environments.